The Wacky Dr. Waksal
On Dec. 5, 2001, ImClone Systems, a biotech company that was seeking Food and Drug Administration approval for a promising anti-cancer drug called Erbitux, saw its stock peak at a price of $74 a share and begin an earthward trajectory.
On the evening of Dec. 6, ImClone’s chief executive, Sam Waksal, 54, threw his annual Read More
